362 related articles for article (PubMed ID: 29588349)
1. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
2. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways.
Song NY; Zhu F; Wang Z; Willette-Brown J; Xi S; Sun Z; Su L; Wu X; Ma B; Nussinov R; Xia X; Schrump DS; Johnson PF; Karin M; Hu Y
Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E812-E821. PubMed ID: 29311298
[TBL] [Abstract][Full Text] [Related]
3. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
4. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
Hong BJ; Park WY; Kim HR; Moon JW; Lee HY; Park JH; Kim SK; Oh Y; Roe JS; Kim MY
Cancer Res; 2019 Nov; 79(22):5849-5859. PubMed ID: 31506334
[TBL] [Abstract][Full Text] [Related]
6. IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells.
Rodrigues FS; Miranda VS; Carneiro-Lobo TC; Scalabrini LC; Kruspig B; Levantini E; Murphy DJ; Bassères DS
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823550
[TBL] [Abstract][Full Text] [Related]
7. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
8. Regulation and function of IKK and IKK-related kinases.
Häcker H; Karin M
Sci STKE; 2006 Oct; 2006(357):re13. PubMed ID: 17047224
[TBL] [Abstract][Full Text] [Related]
9. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
11.
Skoulidis F; Goldberg ME; Greenawalt DM; Hellmann MD; Awad MM; Gainor JF; Schrock AB; Hartmaier RJ; Trabucco SE; Gay L; Ali SM; Elvin JA; Singal G; Ross JS; Fabrizio D; Szabo PM; Chang H; Sasson A; Srinivasan S; Kirov S; Szustakowski J; Vitazka P; Edwards R; Bufill JA; Sharma N; Ou SI; Peled N; Spigel DR; Rizvi H; Aguilar EJ; Carter BW; Erasmus J; Halpenny DF; Plodkowski AJ; Long NM; Nishino M; Denning WL; Galan-Cobo A; Hamdi H; Hirz T; Tong P; Wang J; Rodriguez-Canales J; Villalobos PA; Parra ER; Kalhor N; Sholl LM; Sauter JL; Jungbluth AA; Mino-Kenudson M; Azimi R; Elamin YY; Zhang J; Leonardi GC; Jiang F; Wong KK; Lee JJ; Papadimitrakopoulou VA; Wistuba II; Miller VA; Frampton GM; Wolchok JD; Shaw AT; Jänne PA; Stephens PJ; Rudin CM; Geese WJ; Albacker LA; Heymach JV
Cancer Discov; 2018 Jul; 8(7):822-835. PubMed ID: 29773717
[No Abstract] [Full Text] [Related]
12. PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
Meeusen B; Cortesi EE; Domènech Omella J; Sablina A; Ventura JJ; Janssens V
Cancer Lett; 2021 Nov; 520():57-67. PubMed ID: 34216687
[TBL] [Abstract][Full Text] [Related]
13. PKC
Garg R; Cooke M; Benavides F; Abba MC; Cicchini M; Feldser DM; Kazanietz MG
Cancer Res; 2020 Dec; 80(23):5166-5173. PubMed ID: 32994205
[TBL] [Abstract][Full Text] [Related]
14. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
16. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
17. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
[TBL] [Abstract][Full Text] [Related]
18. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L; Wang H; Nieto P; Zheng J; Blanco-Aparicio C; Varela C; Gómez-López G; Fernández-García F; Sanclemente M; Guerra C; Drosten M; Galán J; Caleiras E; Martínez-Torrecuadrada J; Fajas L; Peng SB; Santamaría D; Musteanu M; Barbacid M
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24415-24426. PubMed ID: 32913049
[TBL] [Abstract][Full Text] [Related]
19. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Ambrogio C; Köhler J; Zhou ZW; Wang H; Paranal R; Li J; Capelletti M; Caffarra C; Li S; Lv Q; Gondi S; Hunter JC; Lu J; Chiarle R; Santamaría D; Westover KD; Jänne PA
Cell; 2018 Feb; 172(4):857-868.e15. PubMed ID: 29336889
[TBL] [Abstract][Full Text] [Related]
20. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
